Related Experiment Video
Updated: Mar 10, 2026
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
The coronary sinus reducer: clinical evidence and technical aspects
Francesco Giannini1,2, Andrea Aurelio1,3, Richard J Jabbour1,2
1a Interventional Cardiology Unit , San Raffaele Hospital , Milan , Italy.
Insights
The Coronary Sinus Reducer offers a new treatment for chronic refractory angina in patients ineligible for surgery. This device improved symptoms in a recent clinical trial, addressing an unmet need for effective therapies.
Area of Science:
- Cardiology
- Interventional Cardiology
- Medical Devices
Background:
- Chronic refractory angina significantly impacts quality of life and exercise capacity.
- Patients often remain symptomatic despite optimal medical therapy and are not candidates for revascularization.
- There is a critical unmet need for novel therapies to manage refractory angina and reduce healthcare costs.
Purpose of the Study:
- To review the clinical evidence and technical aspects of the Coronary Sinus Reducer.
- To evaluate the efficacy of the Coronary Sinus Reducer in patients with refractory angina unsuitable for revascularization.
Main Methods:
- Review of clinical evidence and technical aspects of the Coronary Sinus Reducer.
- Analysis of a randomized, double-blind, multi-center clinical trial involving 104 refractory angina patients.
- Comparison of the Coronary Sinus Reducer against a placebo.
Main Results:
- The Coronary Sinus Reducer is a percutaneous device designed to narrow the coronary sinus.
- Potential mechanisms include improved blood redistribution and promotion of neoangiogenesis.
- A clinical trial demonstrated a statistically significant benefit in symptom improvement compared to placebo.
Conclusions:
- The Coronary Sinus Reducer represents a promising new therapeutic option for refractory angina.
- This device may alleviate myocardial ischemia by altering coronary sinus hemodynamics.
- Further evaluation is warranted to establish its role in managing this challenging patient population.
Introduction:
Chronic refractory angina is often a disabling condition, predominantly due to severe obstructive coronary artery disease, that is inadequately controlled by optimal medical therapy and not amenable to further percutaneous or surgical revascularization. mortality rates associated with this condition are relatively low in clinically stable patients. however, it is associated with a high hospitalization rate and a reduction in both exercise capacity and quality of life. due to the paucity of available treatment options, there is an unmet need for new therapies for these patients and for a reduction in the associated economic healthcare burden. Areas covered: This review is focusing on the clinical evidence and technical aspects of this new therapeutic modality in refractory angina patients unsuitable for revascularization. Expert commentary: The Coronary Sinus Reducer (Neovasc Inc. Richmond B.C., Canada) is a new percutaneous device designed to achieve a controlled narrowing of the coronary sinus that may alleviate myocardial ischemia, possibly by redistributing blood from the less ischemic sub-epicardium to the more ischemic sub-endocardium, or by neoangiogenesis. Recently, a randomized, double-blind, multi-center clinical trial demonstrated a benefit in improving symptoms in 104 refractory angina patients, when compared to placebo.
Related Concept Videos
01:27Coronary Artery Disease V: Interprofessional Care
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:30Coronary Artery Disease III: Clinical Manifestations
01:26Coronary Artery Disease IV: Preventive Measures
01:26Acute Coronary Syndrome V: Nursing Management